Donanemab (Eli Lilly), an amyloid plaque-targeting mAb, has completed a phase 3 trial and was undergoing regulatory review at the time of writing. Based on learnings in the field over the past two ...

Donanemab is unlike most other amyloid-targeting drugs – including aducanumab – because it targets a pyroglutamated form of amyloid beta called N3pG that is found only in amyloid plaques and ...

Unlike the previous two approvals, this new therapeutic, named donanemab, targets amyloid beta only at a later stage when it has clumped together to form plaques. It offers similar efficacy to ...

A new drug, donanemab, is being hailed as a turning ... also known as a placebo, over 18 months. Amyloid is just one part of the complex picture of Alzheimer's, and it is unclear if the treatment ...

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also new findings that reinforce its benefits in ...

Treatment with donanemab reduced amyloid plaque on average by 84% at 18 months, Lilly found. How are the drugs given?

Treatment with donanemab reduced amyloid plaque on average by 84% at 18 months, Lilly found. – How are the drugs given?

Patients and their families want and deserve access to treatment with amyloid targeting therapies, which could give them more time to do the things that matter most to them in the early ...

The company Eli Lilly has reported its drug - donanemab - slows the pace of ... to clear a sticky gunk from the brain, called beta amyloid. Amyloid builds up in the spaces between brain cells ...

Donanemab works by removing a sticky protein, beta amyloid plaque, from the brain. Such plaque build-up is hypothesized to be a cause of Alzheimer's disease. Tau plaque is also thought to ...

What You Need to Know Donanemab (Kisunla) and lecanemab (Leqembi) slow early-stage Alzheimer’s progression by targeting beta-amyloid... A new study links Alzheimer’s in mothers to more ...